Small anticancer drug release by light
Aiming to engineer simple, neutral, strongly amphiphilic photoactive nanoparticles (NPs) to specifically target cancer cell lysosomes for drug transport and
A forum for researchers, students and applicants in the field of cyclodextrin technology
Aiming to engineer simple, neutral, strongly amphiphilic photoactive nanoparticles (NPs) to specifically target cancer cell lysosomes for drug transport and
Cyclodextrins (CDs) attracted increasing interest over the past few years, leading to the emergence of promising anti-tumor nanomedicines. Tackling their
In a recent study published in Science Advances, Diptiman Choudhury, a biochemist at the Thapar Institute of Engineering and Technology,
In the past few years, drug delivery systems have been used extensively to improve solubility, stability, and pharmacokinetics of chemotherapeutic
Immune system deficiencies are crucial in the progression of cancer, predominantly because immune cells are not stimulated by cytokines to
The aim of this study was to evaluate the interaction between catanionic vesicles based on amphiphilic cyclodextrins (ModCBHD) and DNA–Doxorubicin
Phytocannabinoids possess anticancer properties, as established in vitro and in vivo. However, they are characterized by high lipophilicity. To improve
In the last decade, nanotechnological progress has generated new opportunities to improve the safety and efficacy of conventional anticancer therapies.
This review of Rincón-López et al. (2021) was published in the special issue Pharmaceutical and Biomedical Applications of Cyclodextrins and
The team of Motoyama in Kumamoto has recently published new results on folate-appended CDs in leukemia and ovarian cancer (1,2).